Development of resistance of zidovudine (ZDV) and didanosine (ddI) in HIV from patients in ZDV, ddI and alternating ZDV/ddI therapy.

doi:10.1097/00002030-199606000-00008

Back to search

Article

Development of resistance of zidovudine (ZDV) and didanosine (ddI) in HIV from patients in ZDV, ddI and alternating ZDV/ddI therapy.

AIDS (London, England) - 1 Jun 1996

Nielsen C, Bruun L, Mathiesen L R, Pedersen C, Gerstoft J

Abstract excerpt

OBJECTIVE: To study development of phenotypic and genotypic resistance against zidovudine (ZDV) and didanosine (ddI) during 24 months of mono- and monthly alternating therapy. PATIENTS: Forty-six patients, not previously treated with antiretroviral drugs, were included in the study. METHODS: ZDV...

Topics

Anti-HIV Agents
CD4-Positive T-Lymphocytes
Cells, Cultured
Didanosine
Drug Resistance
HIV Infections
HIV-1
Humans
Mutation
Zidovudine

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.